Ilyang Pharmaceutical Co Ltd
KRX:007570
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9 580
15 130
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
I
|
Ilyang Pharmaceutical Co Ltd
KRX:007570
|
233.9B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
992.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
541.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
270B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
218.4B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
94.9B EUR |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
Ilyang Pharmaceutical Co Ltd
Glance View
Il-Yang Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Yongin, Gyeonggi-Do. The firm mainly manufactures and sells pharmaceutical products including prostatitis agents, anti-inflammatory drugs, diabetic agents, gastritis agents, and others. The firm also produces products including nourishing tonics and health supplements, among others.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Ilyang Pharmaceutical Co Ltd is 2.2%, which is below its 3-year median of 5.6%.
Over the last 3 years, Ilyang Pharmaceutical Co Ltd’s Operating Margin has decreased from 12.1% to 2.2%. During this period, it reached a low of 2.2% on Sep 30, 2025 and a high of 12.1% on Sep 30, 2022.